Tags: severe asthma | mepolizumab | clinical trials | non-inhaled asthma treatment | eosinophilic asthma

New Asthma Drug Effective in Trials

Thursday, 13 Mar 2014 12:04 PM


GlaxoSmithKline Plc said its non-inhaled treatment for a type of severe asthma met the main goals in two late-stage studies.
In one study, the treatment, mepolizumab, showed statistically significant reduction in the frequency of exacerbations in patients of severe eosinophilic asthma compared with a placebo, GSK said on Wednesday.
The second study showed that patients on mepolizumab achieved greater reduction in their oral corticosteroid dose compared with those on placebo, while maintaining asthma control.
The company said the drug was administered to patients intravenously or through subcutaneous injections every four weeks in the first study.
In the second trial, the drug was administered through subcutaneous injections.
The company said it would file for regulatory approval for the drug globally by the end of the year.
GSK's shares closed 1.5 percent lower at 1670.5 pence on Wednesday on the London Stock Exchange.

© 2017 Thomson/Reuters. All rights reserved.

   
1Like our page
2Share
Health-News
GlaxoSmithKline Plc said its non-inhaled treatment for a type of severe asthma met the main goals in two late-stage studies. In one study, the non-inhaled treatment, mepolizumab, showed statistically significant reduction in the frequency of exacerbations in patients of severe...
severe asthma,mepolizumab,clinical trials,non-inhaled asthma treatment,eosinophilic asthma
141
2014-04-13
Thursday, 13 Mar 2014 12:04 PM
Newsmax Inc.
 

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved